Celldex Therapeutics reported $-27696000 in Operating Profit for its third fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Operating Profit Change
Abbvie ABBV:US USD 4.6B 1.31B
Agenus AGEN:US USD -41645000 2.92M
Amgen AMGN:US USD 2.74B 562M
Applied Genetic Technologies AGTC:US USD -17344000 380K
Aptinyx Inc APTX:US USD -14657000 2.45M
Biocept BIOC:US USD -5577000 480K
Bristol Myers Squibb BMY:US USD 2.47B 117M
Celldex Therapeutics CLDX:US USD -27696000 8.7M
Cytrx CYTR:US USD -1294610 7.73M
Glaxosmithkline GSK:US GBP 1.19B 110M
Immunogen IMGN:US USD -77429000 16.38M
Nektar Therapeutics NKTR:US USD -54301000 98.54M
Newlink Genetics NLNK:US USD -7550000 374K
Northwest Biotherapeutics NWBO:US USD -16074000 5.14M
Pfizer PFE:US USD 9.41B 2.69B
Rigel Pharmaceuticals RIGL:US USD -18403000 5.44M
Seattle Genetics SGEN:US USD -192805000 59.69M